09/09/2016

MolecuLight Inc

MolecuLight to make its MEDICA debut featuring first-of-its-kind wound bacteria imaging device that guides care

FOR IMMEDIATE RELEASE

 MolecuLight to make its MEDICA debut featuring first-of-its-kind wound bacteria imaging device that guides care

Handheld fluorescence imaging allows bedside clinicians to instantly reveal and identify potentially harmful bacteria in wounds and chronic ulcers, speeding treatment and healing

TORONTO,  Sept. 9, 2016 – MolecuLight Inc. will make its first appearance at MEDICA, the world’s largest annual medical trade fair November 14-17 in Düsseldorf, Germany where it will feature the company’s first product, the MolecuLight i:X™. The patented portable device uses fluorescence imaging technology to visualize potentially harmful amounts of bacteria in wounds that might otherwise go unnoticed. The MolecuLight i:X camera captures real time images of bacteria without the use of contrasting agents and with no patient contact.

“It’s this ability to see and know where the bacteria are at the point of care that allows the clinician to implement more targeted treatment protocols, therefore improving the rate of wound closure,” explains Craig Kennedy, MolecuLight’s CEO.

A 2015 peer-reviewed study published by PLOS One found during a six-month trial that diabetic foot ulcers, when incorporating autofluorescence into the standard of care to accurately guide treatment, closed nine times faster. In another case study published in the International Wound Journal, researchers used the MolecuLight i:X to detect an infection hidden under the skin of a hospital patient who was about to be discharged. Had this infection not been caught prior to discharge, the patent may have had serious complications at home. 

In 2007 when working on his doctorate, MolecuLight’s founder and Chief Scientific Officer, Dr. Ralph DaCosta, accidentally discovered that bacteria can be made to fluoresce. Then, as a fully-qualified molecular imaging scientist, Dr. DaCosta went on to develop what is now the MolecuLight i:X at the Princess Margaret Cancer Centre and Techna Institute, both part of Toronto’s renowned University Health Network. The UHN is a healthcare grouping of four major hospitals and related institutes, renowned for its medical research and development.

The MolecuLight i:X is currently licensed for sale in Canada, and is being used by over 20 clinicians.

About MolecuLight:
Founded in 2012, and based in Toronto, Canada, MolecuLight Inc. is a privately-owned medical imaging company delivering fluorescence image-guidance solutions that provide clinicians with visual information about wound bacterial burden for better diagnostic and treatment decisions.

MolecuLight strives to become the ubiquitous name in fluorescence-guided wound imaging technologies and to serve the healthcare industry with world-class products and services while delivering value to all customers, employees and shareholders.
 
Note: The MolecuLight i:X Imaging Device is approved by Health Canada (Medical License #95784) for use in Canada.  The device is pending FDA De Novo clearance and CE mark approval, which lead to approved use in the United States and Europe respectively.

To learn more about MolecuLight, please visit us during MEDICA 2016 at the Ontario/Canada Pavilion, Hall 16, Booth G42.

You can also locate us in “Companies & Products" on the medica-tradefair.com portal. 

Media Contact:
Catherine Theodoropoulos, PhD
VP Marketing & Product Strategy
MaRS Centre, South Tower
101 College St., Suite 200
Toronto, ON  M5G 1L7  Canada
T: 416.673.6515
www.moleculight.com

 

 

-30-

Exhibitor Data Sheet